FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

BPC-157

Body Protection Compound-157 / Bepecin / PL 14736 / PL-10

Recovery & Repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively researched peptides in preclinical models, with over 100 published studies demonstrating tissue-healing properties across tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system. Despite robust animal data, no completed human clinical trials exist as of 2024.

Meccanismo d'azione

Pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation, accelerates tendon and ligament healing, modulates nitric oxide signaling, and protects endothelial cells. Demonstrates systemic healing properties across multiple tissue types.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Research protocols use 200-500mcg once or twice daily via subcutaneous injection near the injury site or systemically. Cycles of 4-12 weeks. Some protocols use oral administration at higher doses (500mcg-1mg).

Note di ricerca

Clinical Research Status

No completed human clinical trials. Extensive preclinical data across 100+ published studies in animal models. Currently being investigated by companies including Stabilitech Biopharma (oral formulation).

Key Published Findings

Demonstrated accelerated healing in rat models of Achilles tendon transection, medial collateral ligament rupture, and muscle crush injuries. Shown to promote angiogenesis (new blood vessel formation) through upregulation of VEGF and its receptor. Exhibits cytoprotective effects against NSAID-induced gastric damage in multiple studies.

Safety Profile

No significant toxicity reported in animal studies at standard research doses. No LD50 has been established (no lethal dose found). Remarkably wide safety margin in preclinical testing. Long-term human safety data does not exist.

Drug Interactions & Contraindications

May interact with dopaminergic and serotonergic systems. Shown to counteract the effects of dopamine agonists and antagonists in animal models. Potential interactions with medications affecting the nitric oxide system. Caution advised when combining with other growth-promoting compounds.

Comparison to Related Compounds

Often compared to and stacked with TB-500 (Thymosin Beta-4). BPC-157 tends to be more localized in its healing effects while TB-500 is more systemic. Unlike most peptides, BPC-157 is stable at gastric pH, enabling oral administration without significant degradation.

Community Observations

Widely used in the biohacking and athletic recovery community. Anecdotal reports consistently describe accelerated recovery from soft tissue injuries. Some users report improved gut function and reduced inflammation. Injection site reactions are the most commonly reported side effect.

Semplifichro

~4 hours

Riconcimimento

Bacteriostatic water (BAC)

Conservazione

Lyofilizzato

Refrigerate 2-8C up to 24 months. Protect from light.

Riconcimato

Refrigerate 2-8C. Use within 14 days.

Stato legale USA

Research chemical (not FDA-approved)

Anche noto come

Body Protection Compound-157BepecinPL 14736PL-10

Domande frequenti

Che cos'è BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively researched peptides in preclinical models, with over 100 published studies demonstrating tissue-healing properties across tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system. Despite robust animal data, no completed human clinical trials exist as of 2024.

Come agisce BPC-157?

Pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation, accelerates tendon and ligament healing, modulates nitric oxide signaling, and protects endothelial cells. Demonstrates systemic healing properties across multiple tissue types.

Qual è lo stato normativo di BPC-157 negli Stati Uniti?

Research chemical (not FDA-approved)

Qual è l'emivita di BPC-157?

~4 hours

Con quali altri nomi è noto BPC-157?

Body Protection Compound-157, Bepecin, PL 14736, PL-10

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità